Daiichi Sankyo hands off cancer drug to Boston Pharma

The Japanese pharma sold off a cancer compound from its crowded portfolio to Boston Pharmaceuticals, where it may have a better chance of moving to market

By Suzanne Elvidge • Aug. 29, 2017

Kite flying high on $12B takeout by Gilead

The big biotech, long under pressure to make a deal, is using part of its cash stockpile to pick up the hot CAR-T company. 

By Lisa LaMotta • Aug. 28, 2017

Xoma clears debt with Novartis licensing deal

The big pharma will spend $31 million upfront and pay down part of Xoma's debt to gain access to the biotech's anti-inflammatory drug. 

By Suzanne Elvidge • Aug. 28, 2017

Prescribed Reading: Biosimilars or biologics? Why not both?

A few small deals, plenty of stock movement on clinical trial results and several new therapies inch closer to market. 

By Lisa LaMotta • Aug. 25, 2017

Regenxbio picks up Dimension in $86M stock deal

The all-stock acquisition will give Regenxbio access to one clinical and several preclinical gene therapy candidates.

By Ned Pagliarulo • Aug. 25, 2017

Dr. Reddy's sells off psoriasis candidate in out-licensing deal

In the midst of a challenging year, the Indian drugmaker inked a deal that could be worth up to $32.5 million in milestone payments. 

By Suzanne Elvidge • Aug. 23, 2017

Novogen irons out Phase 2 plans for brain cancer candidate

Contract research organization Chiltern will help the company conduct a mid-stage study slated for the fourth quarter.

By Jacob Bell • Aug. 22, 2017

Stada takeover inches closer

Cinven and Bain have cleared the first hurdle to a Stada takeover with more than 63% shareholder acceptance — but there's still a ways to go.

By Suzanne Elvidge • Aug. 22, 2017

AstraZeneca taps Ethris in RNA deal

The five-year deal focuses on discovery and development of respiratory treatments, adding to the big pharma's growing respiratory portfolio.

By Suzanne Elvidge • Aug. 22, 2017

Mundipharma picks up chemo prodrug in $250M deal

Known as CAP7.1, the drug is a reformulated version of the generic agent etoposide and is designed to treat biliary tract cancer.

By Ned Pagliarulo • Aug. 15, 2017

Canadian drugmaker Prometic closes China JV deal

The Chinese pharmaceutical market is expected to grow dramatically, leading Western biopharmas to explore new partnerships and investments. 

By Suzanne Elvidge • Aug. 15, 2017

Fortress adds 10th subsidiary to biotech network

The hyrbid biopharma/venture firm launched Aevitas Therapeutics Monday to develop gene therapies for two rare diseases.

By Suzanne Elvidge • Aug. 15, 2017

Prescribed Reading: Merger as a band-aid for biotech troubles

Multiple biotechs with ongoing problems discovered solutions this week by merging with privately held companies, which could offer a needed boost. 

By Lisa LaMotta • Aug. 11, 2017

GSK drops two Ionis drugs in pipeline revamp

The British pharma, fresh off a review of its rare disease business, decided not to exercise options on inotersen and IONIS-FB-LRx.

By Jacob Bell • Aug. 11, 2017

Melinta grows pipeline through reverse merger with Cempra

The new company will focus on commercializing the pneumonia drug Baxdela and further developing its antibiotic platform.

By Jacob Bell • Aug. 9, 2017

Troubled Galena swallowed by Sellas

Sellas will take over the assets of struggling Galena in a reverse merger that allows the closely held company to go public.

By Lisa LaMotta • Aug. 9, 2017

Roche sells off dermatitis drug to Dermira

Lebrikizumab has had disappointing clinical results to date, yet Dermira hopes the IL-13 inhibitor could prove itself in the emerging atopic dermatitis space. 

By Ned Pagliarulo • Aug. 8, 2017

Mallinckrodt snaps up pediatric jaundice drug

The specialty pharma goes shopping in the baby-care aisle to pick up InfaCare and its pipeline of newborn medications.

By Suzanne Elvidge • Aug. 7, 2017

BMS boosts I/O pipeline with IFM acquisition

Bristol-Myers Squibb is buying its way into another immuno-oncology approach as it tries to maintain a leadership position. 

By Suzanne Elvidge • Aug. 4, 2017

Prescribed Reading: More portfolios reshuffled

Restructuring continued throughout the industry, as more companies attempt to cut costs or excess programs. Meanwhile, the FDA kept up its rapid pace of drug approvals.

By Lisa LaMotta • Aug. 4, 2017

Closing Claris deal, Baxter set to invest in three new plants

Baxter expects the injectable drugmaker will bring it $55 million worth of incremental sales during 2017.

By Jacob Bell • Aug. 3, 2017

Allergan's Saunders 'cautiously optimistic' on healthcare reform

The outspoken CEO talked Washington and drug pricing, as well as dealmaking, during a second quarter earnings call with analysts.

By Lisa LaMotta • Aug. 3, 2017

23andMe, Lundbeck unveil mega investigation of genetics' role in depression

Enrollment has already begun for the 25,000-person investigation.

By Jacob Bell • Aug. 2, 2017

Chiesi hands back gene therapy to uniQure

On the heels of Glybera's commercial flop, uniQure loses its development partner for a gene therapy currently in mid-stage testing for hemophilia B.

By Lisa LaMotta • Aug. 1, 2017

Bristol-Myers, Clovis ink industry's latest PARP deal

The companies plan to investigate the combination of Opdivo and Rubraca as a treatment for various cancers.

By Jacob Bell • Aug. 1, 2017